Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Bibliographic Details
Main Authors: Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Format: Online
Language:English
Published: Nature Publishing Group 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119993/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119993/

Similar Items